Wavewise Analytics

Wavewise Analytics operates in medical devices and health diagnostics, with a focus on brain oxygen monitoring for brain-injury care. Its Brain Pulse Monitor is described as a non-invasive device intended to track oxygen levels continuously from the trauma site through hospital discharge, placing the product in a specialized clinical-monitoring use case rather than general-purpose health tracking. The company’s stated areas of expertise span neuroscience, medical devices, and critical care, and its positioning centers on supporting frontline healthcare teams and patient care. Its funding history includes two Series A rounds totaling USD 11.5 million, plus a 2025 grant of USD 644,956. The available comparable-company entries repeat Wavewise Analytics itself, so they do not provide a reliable basis for naming direct competitors or benchmarking its market share. As a result, its competitive differentiation can be described at the product and use-case level, but not through a verified competitor comparison or evidence of commercial adoption.

Wavewise Analytics was founded in 2019 and has recorded four funding rounds: a seed round dated Jan 1, 2020 with no amount disclosed, a USD 5.25 million Series A on May 18, 2022, a USD 6.25 million Series A on Dec 11, 2023, and a USD 644,956 grant on Jun 20, 2025. The two Series A rounds represent a combined USD 11.5 million and mark the largest documented financing milestones. The company’s Brain Pulse Monitor gives its development effort a defined product focus: non-invasive, continuous monitoring of brain oxygen levels across the care journey from trauma to hospital discharge. Elliot Teo started as Head of Research in October 2024, adding a recorded research leadership appointment. The record indicates that the company invites people to explore careers, but it does not identify open roles, launch dates, or clinical or commercial deployment milestones.